Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

A New MRI-Based Malignancy Grading System for Parotid Mucoepidermoid Carcinoma.

Created on 21 Sep 2026

Authors

Masaaki Higashino, Ryo Kawata, Toshihiro Matsuoka, Akira Higashiyama, Ichita Kinoshita, Masataka Taniuchi, Tsuyoshi Jinnin, Hiroko Kuwabara, Yoshinobu Hirose, Keigo Osuga, Shin-Ichi Haginomori

Published in

Head & neck. Sep 20, 2026. Epub Sep 20, 2026.

Abstract

To improve the diagnosis of malignancy grade in parotid mucoepidermoid carcinoma using preoperative MRI.
Among 46 cases of parotid mucoepidermoid carcinoma, MRI findings were compared between low/intermediate malignancy and high malignancy. Primary lesions were assessed based on eight parameters. The scores were assigned to create criteria for diagnosing the malignancy grades on MRI. MRI diagnosis was compared with the diagnosis of malignancy grade using fine needle aspiration cytology and frozen section.
High-grade malignancy showed distinctive changes in the maximum tumor diameter, shape, cystic component, margin, and necrotic areas. The MRI score of ≥ 6 was graded as a high-grade malignancy, the diagnostic accuracy was 89%. In contrast, the accuracy of fine needle aspiration cytology, and frozen section for the grade of malignancy was 52% and 22%, respectively.
MRI scoring was found to be useful for determining the grade of malignancy of parotid mucoepidermoid carcinoma.

PMID:
42764712
Bibliographic data and abstract were imported from PubMed on 21 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 14
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement